Wize Pharma

Treatments for Ophthalmic Disorders

Health Tech & Life Sciences
Acquired (Inactive) by - on Mar 2021 - closed due to acquisition

Company Overview

Snapshot

Founded in June 1982 by Gideon Stein, Wize Pharma operates with 1-10 employees. The company has raised $5.21 million across 3 funding rounds from 1 investor. In March 2021, Wize Pharma was acquired, leading to its delisting from the Gvool Dotcom stock exchange.

Business overview

Wize Pharma is a clinical-stage biopharmaceutical company focused on developing treatments for ophthalmic disorders, including dry eye syndrome (DES) and other inflammatory conditions. The company has in-licensed rights to LO2A, a drug designed for DES and other ophthalmological illnesses like CCH and Sjögren's syndrome. LO2A is currently marketed in Germany, Switzerland, Hungary, and the Netherlands. Wize Pharma's strategy involves engaging distributors for LO2A and has completed a Phase 2 trial for CCH and a Phase 4 study for DES in Sjögren's patients. The company operates in the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, targeting the pharmaceutical market.

Company Intelligence Q&A

What was a significant corporate event for Wize Pharma in March 2021?
In March 2021, Wize Pharma was acquired and subsequently delisted from the Gvool Dotcom stock exchange. The company also announced its intention to change its name to Mawson Infrastructure Group Inc.
What was the outcome of Wize Pharma's Phase IV study for LO2A in November 2020?
In November 2020, Wize Pharma announced positive topline results from its Phase IV study of LO2A for the treatment of dry eye syndrome in patients with Sjögren's Syndrome.
What strategic transaction did Wize Pharma complete in February 2020?
In February 2020, Wize Pharma completed a strategic transaction with Bonus BioGroup, following agreements executed in January 2020.
What was a key development regarding Wize Pharma's LO2A product in April 2019?
In April 2019, Wize Pharma announced positive results in the first controlled study of LO2A for the treatment of dry eye syndrome in patients with conjunctivochalasis.
What was the purpose of the joint venture Wize Pharma closed in March 2019?
In March 2019, Wize Pharma closed a deal to launch a joint venture with Cannabics to research and develop cannabinoid formulations for treating ophthalmic conditions. This joint venture completed a milestone in June 2019.

External links